Shots:
Italfarmaco & JCR Pharmaceuticals have entered an exclusive license agreement to develop & potentially commercialize JR-141 (pabinafusp alfa) in the US, Europe, & Latin America for Hunter syndrome (MPS II)
The companies seek approvals for JR-141 in the US, EU, UK & Brazil. Following approval, Italfarmaco will commercialize & distribute JR-141 in licensed territories,…
